Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
12.1 EUR | 0.00% |
|
0.00% | -6.20% |
Jul. 09 | Takeda Issues New Shares, Disposes of Treasury Shares Under Incentive Scheme | MT |
Jul. 03 | Blackstone selling Japan drugmaker Alinamin to MBK Partners | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 58.67 and 31.14 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.20% | 41.59B | - | ||
+59.97% | 840B | C+ | ||
+38.38% | 621B | B | ||
-6.18% | 354B | C+ | ||
+15.61% | 319B | B- | ||
+8.44% | 297B | C+ | ||
+12.68% | 237B | B+ | ||
+14.40% | 221B | B- | ||
+0.04% | 220B | A+ | ||
+9.68% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- TKDA Stock
- Ratings Takeda Pharmaceutical Company Limited